Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial

被引：6

作者：

van Nes, J. G. H. ^{[1
]}

Seynaeve, C. ^{[2
]}

Maartense, E. ^{[3
]}

Roumen, R. M. H. ^{[4
]}

de Jong, R. S. ^{[5
]}

Beex, L. V. A. M. ^{[6
]}

Kranenbarg, W. M. Meershoek-Klein ^{[7
]}

Putter, H. ^{[8
]}

Nortier, J. W. R. ^{[9
]}

van de Velde, C. J. H. ^{[1
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands

[2] Daniel Denhoed Canc Ctr, Erasmus Med Ctr, Dept Med Oncol, Rotterdam, Netherlands

[3] Reinier Graaf Gasthuis, Dept Internal Med, Delft, Netherlands

[4] Maxima Med Ctr, Dept Surg, Veldhoven, Netherlands

[5] Martini Hosp, Dept Internal Med, Groningen, Netherlands

[6] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands

[7] Leiden Univ, Med Ctr, Datactr Surg, NL-2300 RC Leiden, Netherlands

[8] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands

[9] Leiden Univ, Med Ctr, Dept Med Oncol, NL-2300 RC Leiden, Netherlands

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷 / 05期

关键词：

breast cancer; endocrine therapy; guideline; patterns of care; AROMATASE INHIBITORS; THERAPY; WOMEN; SURVIVAL; RECOMMENDATIONS; NETHERLANDS; MASTECTOMY; MANAGEMENT; LETROZOLE; SURGERY;

D O I：

10.1093/annonc/mdp419

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Methods: Clinicopathological characteristics, carried out local treatment strategies and adjuvant chemotherapy data were collected. Results: From 2001 to January 2006, 2754 Dutch patients were randomised to the study. Mean age of patients was 65 years (standard deviation 9). Tumours were < 2 cm in 46% (within CCCRs 39%-50%), node-negative disease varied from 25% to 45%, and PgR status was determined in 75%-100% of patients. Mastectomy was carried out in 55% (45%-70%), sentinel lymph node procedure in 68% (42%-79%) and axillary lymph node dissections in 77% (67%-83%) of patients, all different between CCCRs (P < 0.0001). Adjuvant chemotherapy was given in 15%-70% of eligible patients (P < 0.001). Discussion: In spite of national guidelines, breast cancer treatment on specific issues widely varied between the various Dutch regions. These data provide valuable information for breast cancer organisations indicating (lack of) guideline adherence and areas for breast cancer care improvement.

引用

页码：974 / 982

页数：9

共 50 条

[21] Physical activity to maintain quality of life in breast cancer survivors in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Voskuil, D. W.
van Nes, J. G.
Junggeburt, J. M.
van Leeuwen, F. E.
van de Velde, C. J.
de Haes, H. C.
[J]. CANCER RESEARCH, 2009, 69 (02) : 277S - 277S
[22] Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the TEAM trial neuropsychological side study
Schilder, C. M.
Seynaeve, C.
Linn, S. C.
Boogerd, W.
Beex, L., V
Gundy, C. M.
Huizenga, H. M.
Nortier, J. W.
v d Velde, C. J.
van Dam, F. S.
Schagen, S. B.
[J]. CANCER RESEARCH, 2009, 69 (02) : 146S - 146S
[23] Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib
Dirix, Luc Yves
Ignacio, Jorge
Nag, Shona
Bapsy, Poonamally
Gomez, Henry
Raghunadharao, Digumarti
Paridaens, Robert
Jones, Stephen
Falcon, Silvia
Carpentieri, Marina
Abbattista, Antonello
Lobelle, Jean-Pierre
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) : 1253 - 1259
[24] Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: Updated results from the TEAM trial neuropsychological side study
Kieffer, J. M.
Small, B. J.
Seynaeve, C.
Boogerd, W.
Kranenbarg, E. Meershoek-Klein
Van de Velde, C. J.
Schagen, S. B.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S271 - S272
[25] Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women
Mauriac, L
Debled, M
Durand, M
Floquet, A
Boulanger, V
Dagada, C
Trufflandier, N
MacGrogan, G
[J]. ANNALS OF ONCOLOGY, 2002, 13 (02) : 293 - 298
[26] Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial
Rossi, Emanuela
Morabito, Alessandro
Di Rella, Francesca
Esposito, Giuseppe
Gravina, Adriano
Labonia, Vincenzo
Landi, Gabriella
Nuzzo, Francesco
Pacilio, Carmen
De Maio, Ermelinda
Di Maio, Massimo
Piccirillo, Maria Carmela
De Feo, Gianfranco
D'Aiuto, Giuseppe
Botti, Gerardo
Chiodini, Paolo
Gallo, Ciro
Perrone, Francesco
de Matteis, Andrea
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3192 - 3197
[27] CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
Dezentje, Vincent O.
Gelderblom, Hans
Van Schaik, Ron H. N.
Vletter-Bogaartz, Judith M.
Van der Straaten, Tahar
Wessels, Judith A. M.
Kranenbarg, Elma Meershoek-Klein
Berns, Els M.
Seynaeve, Caroline
Putter, Hein
Van de Velde, Cornelis J. H.
Nortier, Johan W. R.
Guchelaar, Henk-Jan
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (01) : 171 - 179
[28] Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone-sensitive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)
不详
[J]. EJC SUPPLEMENTS, 2006, 4 (02): : 155 - 156
[29] CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
Vincent O. Dezentjé
Hans Gelderblom
Ron H. N. Van Schaik
Judith M. Vletter-Bogaartz
Tahar Van der Straaten
Judith A. M. Wessels
Elma Meershoek-Klein Kranenbarg
Els M. Berns
Caroline Seynaeve
Hein Putter
Cornelis J. H. Van de Velde
Johan W. R. Nortier
Henk-Jan Guchelaar
[J]. Breast Cancer Research and Treatment, 2014, 143 : 171 - 179
[30] Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer
Tusquets Trias de Bes, Ignasi
Tormo, Sonia Servitja
Mestres, Joan Albanell
[J]. BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (01) : 1 - 10

← 1 2 3 4 5 →